Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases

Background: The characterization of molecular alterations of primary breast carcinomas (BC) and their cutaneous metastases (CM) to identify genes involved in the metastatic process have not yet been completely accomplished. Methods: To investigate the molecular alterations of BC and their CM, a tota...

Full description

Bibliographic Details
Main Authors: Silvia González-Martínez, David Pizarro, Belén Pérez-Mies, Tamara Caniego-Casas, José Luis Rodríguez-Peralto, Giuseppe Curigliano, Alfonso Cortés, María Gión, Javier Cortés, José Palacios
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/14/5/1151
Description
Summary:Background: The characterization of molecular alterations of primary breast carcinomas (BC) and their cutaneous metastases (CM) to identify genes involved in the metastatic process have not yet been completely accomplished. Methods: To investigate the molecular alterations of BC and their CM, a total of 66 samples (33 BC and 33 CM) from 33 patients were analyzed by immunohistochemical and massive parallel sequencing analyses. In addition, the clinicopathological characteristics of patients and tumors were analyzed. Results: Triple negative (TN) BCs were overrepresented (36.4%) among tumors that developed CM. A change of tumor surrogate molecular type in metastases was found in 15% of patients and 48.5% of the CM presented some additional molecular alteration with respect to the primary tumor, the most frequent were amplification of <i>MYC</i> and <i>MDM4</i>, and mutations in <i>TP53</i> and <i>PIK3CA</i>. Survival was related to histological grade, tumor surrogate molecular type and <i>TP53</i> mutations in the univariate analysis but only the tumor surrogate molecular type remained as a prognostic factor in the multivariate analysis. Conclusions: The TN molecular type has a greater risk of developing skin metastases. There are phenotypic changes and additional molecular alterations in skin metastases compared to the corresponding primary breast tumors in nearly half of the patients. Although these changes do not follow a specific pattern and varied from patient to patient, they could impact on the treatment. More studies with larger patient and sample cohorts are needed.
ISSN:2072-6694